Tianjin Pharmaceutical Da Ren Tang Group Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Tianjin Pharmaceutical Da Ren Tang Group wird ein jährliches Gewinn- und Umsatzwachstum von 20.8% bzw. 10.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 20.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 21.3% betragen.

Wichtige Informationen

20.8%

Wachstumsrate der Gewinne

20.9%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	19.3%
Wachstumsrate der Einnahmen	10.9%
Zukünftige Eigenkapitalrendite	21.3%
Analystenabdeckung	Low
Zuletzt aktualisiert	12 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Are Investors Undervaluing Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) By 48%?

Oct 27

Why Investors Shouldn't Be Surprised By Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) 36% Share Price Surge

Oct 08

Some Shareholders Feeling Restless Over Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) P/E Ratio

Jul 26

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Jul 05

Fewer Investors Than Expected Jumping On Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329)

Apr 18

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Mar 18

Gewinn- und Umsatzwachstumsprognosen

SHSE:600329 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	10,457	1,568	N/A	733	2
12/31/2025	9,544	1,337	N/A	1,313	2
12/31/2024	8,725	1,138	N/A	920	2
9/30/2024	8,040	932	1,038	1,175	N/A
6/30/2024	8,099	922	1,008	1,121	N/A
3/31/2024	8,050	915	664	779	N/A
12/31/2023	8,222	987	548	688	N/A
9/30/2023	8,479	991	511	632	N/A
6/30/2023	8,563	1,116	591	711	N/A
3/31/2023	8,514	1,063	679	785	N/A
12/31/2022	8,249	862	569	677	N/A
9/30/2022	7,118	837	188	302	N/A
6/30/2022	7,042	775	433	572	N/A
3/31/2022	6,970	756	656	818	N/A
12/31/2021	6,908	769	695	852	N/A
9/30/2021	6,999	846	770	937	N/A
6/30/2021	6,954	801	570	737	N/A
3/31/2021	6,775	705	472	646	N/A
12/31/2020	6,604	662	482	671	N/A
9/30/2020	6,773	657	425	633	N/A
6/30/2020	6,751	602	414	643	N/A
3/31/2020	6,896	605	291	519	N/A
12/31/2019	6,994	626	290	495	N/A
9/30/2019	6,847	606	125	297	N/A
6/30/2019	6,780	595	111	294	N/A
3/31/2019	6,497	578	109	287	N/A
12/31/2018	6,359	562	174	350	N/A
9/30/2018	6,084	517	154	332	N/A
6/30/2018	5,814	512	N/A	167	N/A
3/31/2018	5,823	516	N/A	170	N/A
12/31/2017	5,689	476	N/A	-4	N/A
9/30/2017	5,747	433	N/A	219	N/A
6/30/2017	5,952	443	N/A	315	N/A
3/31/2017	6,081	438	N/A	304	N/A
12/31/2016	6,243	424	N/A	418	N/A
9/30/2016	6,845	467	N/A	378	N/A
6/30/2016	6,997	471	N/A	280	N/A
3/31/2016	7,104	452	N/A	326	N/A
12/31/2015	7,081	451	N/A	361	N/A
9/30/2015	7,026	436	N/A	208	N/A
6/30/2015	7,114	398	N/A	338	N/A
3/31/2015	7,156	375	N/A	424	N/A
12/31/2014	7,087	358	N/A	287	N/A
9/30/2014	6,621	372	N/A	408	N/A
6/30/2014	6,267	361	N/A	261	N/A
3/31/2014	6,113	336	N/A	158	N/A
12/31/2013	6,010	352	N/A	213	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 600329Das prognostizierte Gewinnwachstum (20.8% pro Jahr) liegt über der Sparquote (2.8%).

Ertrag vs. Markt: 600329Die Erträge des Unternehmens (20.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (25.9% pro Jahr).

Hohe Wachstumserträge: 600329Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: 600329Die Einnahmen des Unternehmens (10.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt CN (13.8% pro Jahr).

Hohe Wachstumseinnahmen: 600329Die Einnahmen des Unternehmens (10.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 600329Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (21.3%)

Tianjin Pharmaceutical Da Ren Tang Group Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Provides Earnings Guidance for the Half Year Ended 30 June 2023

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.19 (vs CN¥0.17 in 3Q 2023)

Are Investors Undervaluing Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) By 48%?

Why Investors Shouldn't Be Surprised By Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) 36% Share Price Surge

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.42 in 2Q 2023)

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) completed the acquisition of additional 15% stake in Tianjin Pharmaceutical Group Finance Co., Ltd from Tianjin Lisheng Pharmaceutical Co.,Ltd. (SZSE:002393).

Some Shareholders Feeling Restless Over Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) P/E Ratio

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited to Report First Half, 2024 Results on Aug 15, 2024

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Final Dividend for the Year Ended December 31, 2023, Payable July 12, 2024

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Directorate and Committee Changes

First quarter 2024 earnings released: EPS: CN¥0.50 (vs CN¥0.52 in 1Q 2023)

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Recommends Dividend

Fewer Investors Than Expected Jumping On Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329)

New major risk - Dividend sustainability

Full year 2023 earnings: EPS and revenues miss analyst expectations

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, Annual General Meeting, May 15, 2024

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited to Report Q1, 2024 Results on Apr 30, 2024

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet

Investor sentiment improves as stock rises 18%

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited to Report Fiscal Year 2023 Results on Mar 30, 2024

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Board Changes

High number of new directors

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Cessation of Zhu Haifeng as an Independent and Non-Executive Director

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Resignation of Mr. Zhu Haifeng as an Independent Director of the Company, as Well as Chairman of Remuneration Committee, and A Member of Each of Audit Committee, the Nomination Committee, and Strategy Committee

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) agreed to acquire additional 15% stake in Tianjin Pharmaceutical Group Finance Co., Ltd from Tianjin Lisheng Pharmaceutical Co.,Ltd. (SZSE:002393) for CNY 87.8 million.

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Appoints Ma Jian as Chief Financial Officer

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Provides Earnings Guidance for the Half Year Ended 30 June 2023

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited to Report First Half, 2023 Results on Aug 15, 2023

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Executive Changes

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Approves Final Dividend for the Financial Period Ended 31 December 2022, Payable on or About 6 June 2023

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Cessation of Wong Gang as Independent and Non-Executive Director

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Resignation of Zhang as Director

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Appoints Wang Lei as General Manager

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Announces Final Dividend for the Financial Period Ended 31 December 2021, to Be Paid on or About 2 June 2022

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Appoints Zhang Yu as Chief Production Officer

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, Annual General Meeting, May 16, 2022

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Recommends to Declare Dividends for the Year Ended 31 December 2021

Tianjin Pharmacy Holdings Co., Ltd. completed the acquisition of 31.02% stake in Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (SGX:T14).

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Announces Cessation of Ni Zhenguo as Deputy General Manager

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited to Report Q3, 2020 Results on Oct 31, 2020

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Declares No Dividend Has for the Half Year Ended June 30, 2020

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited to Report First Half, 2020 Results on Aug 15, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken